Literature DB >> 7298797

Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension.

J R Sowers.   

Abstract

This study examines the influence of dopamine on recumbent circadian mean arterial blood pressure (MAP) levels and secretory patterns of norepinephrine (NE) in essential hypertension. Nine patients with sustained essential hypertension were studied after they had reached metabolic equilibrium of a constant 100-mmol sodium and 80-mmol potassium intake. MAP measurements and plasma NE determinations were made at 30-min intervals over 24 h during a control (no medication) and a bromocriptine (BEC) period (2.5 mg, three times a day for 5 days). In the control period, a clear circadian rhythm in blood pressure was evidenced in these hypertensive patients, with lowest MAP occurring during sleep. NE was secreted in an episodic manner, with most secretory peaks occurring between 0600-1800 h. Sleep was characterized by lower levels of NE than in waking hours and a paucity of secretory peaks. During the control period, recumbent 24-h MAP was strikingly correlated with plasma NE (gamma = 0.67; P less than 0.001). BEC treatment was associated with a depression in MAP throughout the 24-h cycle and a lessening of the relationship between MAP and plasma NE (gamma = 0.35; P less than 0.025). BEC eliminated much of the circadian variation in plasma NE secretion in these hypertensives. Thus, circadian variations in sympathetic nervous system activity and blood pressure in patients with essential hypertension appear to be modulated by a central and/or peripheral dopaminergic mechanism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298797     DOI: 10.1210/jcem-53-6-1133

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Role of dopamine in the regulation of aldosterone and 18-hydroxycorticosterone secretion in man.

Authors:  J R Sowers; F W Beck
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

2.  Circadian variation in plasma dopamine levels in man.

Authors:  J R Sowers; N Vlachakis
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

Review 3.  Cardiovascular effects of melanocortins.

Authors:  Michael H Humphreys; Xi-Ping Ni; David Pearce
Journal:  Eur J Pharmacol       Date:  2011-01-01       Impact factor: 4.432

4.  Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of gamma-melanocyte-stimulating hormone.

Authors:  Xi-Ping Ni; Claudia van Dijk; David Pearce; Michael H Humphreys
Journal:  Exp Physiol       Date:  2009-05-08       Impact factor: 2.969

5.  Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

Authors:  H Przuntek; D Welzel; E Blümner; W Danielczyk; H Letzel; H J Kaiser; P H Kraus; P Riederer; D Schwarzmann; H Wolf
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?

Authors:  M Mannelli; M L De Feo; M Maggi; A Salvetti; G Giusti; M Serio
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Circadian clock-mediated regulation of blood pressure.

Authors:  Lauren G Douma; Michelle L Gumz
Journal:  Free Radic Biol Med       Date:  2017-12-02       Impact factor: 7.376

Review 8.  Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.

Authors:  Minhui Hu; Chunlan Zheng; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2016-12-07       Impact factor: 4.162

9.  Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.

Authors:  Bindu Chamarthi; Aaron Vinik; Michael Ezrokhi; Anthony H Cincotta
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-13

10.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.